MAPT and Alzheimer disease: A visual read method for the Tau-PET radiotracer [18F]flortaucipir was approved by the US Food and Drug Administration (FDA) (in 2020) and the European Medicines Agency (EMA) (in 2024) to support the clinical diagnosis of symptomatic Alzheimer’s disease [11].